PHL-MOXIFLOXACIN TABLET

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

MOXIFLOXACIN (MOXIFLOXACIN HYDROCHLORIDE)

から入手可能:

PHARMEL INC

ATCコード:

J01MA14

INN（国際名）:

MOXIFLOXACIN

投薬量:

400MG

医薬品形態:

TABLET

構図:

MOXIFLOXACIN (MOXIFLOXACIN HYDROCHLORIDE) 400MG

投与経路:

ORAL

パッケージ内のユニット:

10/30/100/500

処方タイプ:

Prescription

治療領域:

QUINOLONES

製品概要:

Active ingredient group (AIG) number: 0142242001; AHFS:

認証ステータス:

CANCELLED PRE MARKET

承認日:

2017-09-13

製品の特徴

PRODUCT MONOGRAPH
PR
PHL-MOXIFLOXACIN
Moxifloxacin tablets
400 mg
(as moxifloxacin hydrochloride)
ANTIBACTERIAL AGENT
PHARMEL INC.
DATE OF REVISION:
6111 Royalmount Avenue, Suite 100
December 23, 2016
Montréal, Quebec, Canada
H4P 2T4
SUBMISSION CONTROL NO:
120275
_ _
_phl-MOXIFLOXACIN Product Monograph _
_Page 2 of 67 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................... 3
SUMMARY
PRODUCT
INFORMATION
...................................................................................
3
INDICATIONS
AND
CLINICAL
USE
.........................................................................................
3
CONTRAINDICATIONS
..............................................................................................................
5
WARNINGS
AND
PRECAUTIONS
.............................................................................................
6
ADVERSE
REACTIONS
............................................................................................................
14
DRUG
INTERACTIONS
.............................................................................................................
18
DOSAGE
AND
ADMINISTRATION
.........................................................................................
21
OVERDOSAGE
...........................................................................................................................
22
ACTION
AND
CLINICAL
PHARMACOLOGY
.......................................................................
23
STORAGE
AND
STABILITY
.....................................................................................................
31
SPECIAL
HANDLING
INSTRUCTIONS
..................................................................................
31
DOSAGE
FORMS,
COMPOSITION
AND
PACKAGING ........................................................ 32
PART II: SCIENTIFIC INFORMATION
..................................................................................
33
PHARMACEUTICAL
INFORMATION
....